Irinto

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinto, is a topoisomerase I inhibitor presented as an intravenous solution for intravenous use. It treats metastatic and advanced colorectal cancer in adult patients.

GNH USA supplies Irinto as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinto (irinotecan) is used in the treatment of colorectal cancer, targeting tumor growth and spread.

Metastatic colorectal cancer: improves overall survival when used in combination chemotherapy regimens. Advanced colorectal cancer: reduces tumor burden and may extend progression‑free survival. Colorectal cancer refractory to standard therapy: provides an additional therapeutic option.

Common Side Effects: - Diarrhea: may be severe and require supportive care. - Nausea and vomiting: often managed with anti‑emetics. - Neutropenia: reduced white blood cell count increasing infection risk. - Alopecia: hair loss during treatment cycles. - Fatigue: general tiredness and weakness. - Elevated liver enzymes: mild hepatic irritation.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count, a medical emergency. - Severe colitis or life‑threatening diarrhea. - Hepatic toxicity: significant liver function impairment. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Cardiac toxicity: rare arrhythmias or myocardial injury. - Secondary malignancies: very rare long‑term risk.

Patients receiving Irinto require careful monitoring and individualized care.

Dose adjustment: required for patients with hepatic impairment. Monitoring: regular complete blood counts to detect neutropenia. Hydration: ensure adequate fluids to mitigate diarrhea. Drug interactions: avoid concurrent strong CYP3A4 inhibitors. Pregnancy: contraindicated or use only if benefits outweigh risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan may interact with several medicines, necessitating vigilance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase toxicity. - Live vaccines: heightened infection risk due to immunosuppression. - Concurrent high‑dose radiation therapy: amplified severe diarrhea. - Other topoisomerase I inhibitors: additive toxicity.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Anticoagulants (e.g., warfarin): monitor INR for bleeding. - Nephrotoxic agents (e.g., cisplatin): watch renal function. - Antidiarrheal agents (e.g., loperamide) at high doses: risk of ileus. - Herbal supplements (e.g., St. John’s wort): possible reduced exposure.